HBV mutation literature information.


  Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy.
 PMID: 35359734       2022       Frontiers in microbiology
Table: I169T


  Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.
 PMID: 33893696       2021       Journal of viral hepatitis
Method: ETV resistance: Two or more amino acid substitutions are required across the HBV RT protein to confer resistance to ETV which could occur as a combination of M204I/V with one or more of the following substitutions L80I/V, I163V, I169T, V173L, L180M, A181S/T/V, T184X, A186T, S202C/G/I/R, M250I/V and/or C256S/G.


  High Prevalence of Preexisting HBV Polymerase Mutations in Pregnant Women Does Not Limit the Antiviral Therapy Efficacy.
 PMID: 33986897       2021       The Canadian journal of infectious diseases & medical microbiology
Result: However, rtI169 T, rtA194 T, rtV173 L, rtL180 M, rtL82 M, rtS85 A, rtV207I, rtL217 R, and rtS/C256G mutations were not present before TBV treatment.


  Detection of Hepatitis B Virus M204V Mutation Quantitatively via Real-time PCR.
 PMID: 34007795       2021       Journal of clinical and translational hepatology
Introduction: In addition to a background of the mutations rtM204V/I, the other mutations, such as rtI169T, rtS184G, rtS202I and rtM250V, are associated with the emergence of ETV resistance.


  Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization.
 PMID: 32216026       2020       Liver international
Abstract: More importantly, the rtI169T mutation in the RT domain, led to the sF161L mutation in the overlapping S gene, which decreased in surface antigenicity.


  Prevalence of Potential Resistance Related Variants Among Chinese Chronic Hepatitis B Patients Not Receiving Nucleos(T)ide Analogues.
 PMID: 32765014       2020       Infection and drug resistance
Abstract: Primary and secondary DR variants were found in 7.3% (15/206) of patients, including rtL80I/V, rtI169T, rtV173L rtL180M, rtA181T/V, rtM204I/V, and rtN236T.
Result: Primary and/or secondary DR variants were found in 7.3% (15/206) of patients, and included rtL80I/V, rtI169T, rt PMID: 30867996       2019       PeerJ
Discussion: M204I/V mutations are frequently accompanied by compensatory mutations in other domains such as 59 rtV173L, rtL180M, rtT184S/G, 58 rtI169T, rtS202I, rtL80V/I and rtQ215S which enhanced the replication efficiency of rt204I/V mutants without significantly affecting lamivudine resistance, by compensating the decrease in efficiency due to resistance-associated changes.


  Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy.
 PMID: 30906435       2019       Experimental and therapeutic medicine
Discussion: Other mutations, including rtV84M, rtN118H/D/T, rtI169T, rtT184A/L/S, rtV191I, rtV207I/M, rtS213T, rtQ215P/S/H, rtI233L, rtP237H/T and rtS202G, which have been previous


  [Determination of reverse transcriptase inhibitor nucleoside analogue resistance profile in pretreatment phase of patients with viral hepatitis B].
 PMID: 31130120       2019       Mikrobiyoloji bulteni
Abstract: Primary drug resistance mutations such as rtI169T, rtA181T/V, rtT184A/C/F/G/I/L/M/S, rtA194T, rtS202C/G/I, rtM204I/V/S, rtN236T, rt M250I/L/V and rtV173L were not detected in any of the patient samples.


  Characterization and Clinical Significance of Natural Variability in Hepatitis B Virus Reverse Transcriptase in Treatment-Naive Chinese Patients by Sanger Sequencing and Next-Generation Sequencing.
 PMID: 31189581       2019       Journal of clinical microbiology
Introduction: For instance, M204V/I in RT (rtM204V/I) is a classical lamivudine (LMV) resistance mutation, which also greatly reduces susceptibility to telbivudine (LdT); rtA181T/V is not only reported as an adefovir dipivoxil (ADV) resistance mutation, but rtA181T/V also confers a decreased susceptibility to LMV, LdT, tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF); rtM204V/I and rtL180M together with rtI169T, rt



   Filtrator